PORT WASHINGTON, N.Y., Sept. 16, 2025 /PRNewswire/ — National law firm Parker Waichman LLP has filed another lawsuit in New Jersey state court on behalf of an individual who developed non-arteritic anterior ischemic optic neuropathy (NAION) after taking Ozempic, a widely prescribed GLP-1 receptor agonist. The latest case, Christensen v. Novo Nordisk Inc., Docket No. MID-L-0056489-25, was filed September 8, 2025, on behalf of a Baltimore, Maryland resident.
This filing adds to a growing number of lawsuits brought by Parker Waichman on behalf of patients who suffered irreversible eye injuries, including partial or complete vision loss, after being prescribed Ozempic or Wegovy.
Serious Risks Tied to Popular Diabetes and Weight Loss Drugs
Originally developed to treat Type 2 diabetes, semaglutide (marketed as Ozempic and Wegovy) has skyrocketed in use for weight loss. However, recent research has linked the drug to NAION, a permanent condition that cuts off blood flow to the optic nerve and can result in blindness.
A 2025 study in JAMA Ophthalmology reported multiple cases of optic nerve disorders among GLP-1 users, most with NAION-like symptoms. Separately, researchers at Harvard’s Mass Eye and Ear Institute found that diabetic patients using semaglutide faced a fourfold increased risk of NAION, while non-diabetic users taking it for weight loss had a sevenfold increased risk.
Despite mounting evidence, Novo Nordisk has not issued adequate warnings about the risk of blindness associated with these drugs.
Parker Waichman LLP Advocates for Victims Nationwide
“NAION is a devastating, permanent eye injury,” said Jason S. Goldstein, Senior Litigation Counsel at Parker Waichman LLP. “Multiple studies from respected institutions confirm a statistically significant link between semaglutide and NAION. Yet, Novo Nordisk continues to deny reality by failing to warn the public and medical professionals. They must be held accountable.”
Parker Waichman LLP is actively reviewing cases nationwide for individuals who have suffered sudden vision loss, blindness, or optic nerve damage after using Ozempic or Wegovy. Potential compensation may include coverage for medical costs, lost income, pain and suffering, and other damages.
Free Case Evaluations Available
Individuals who experienced serious eye injuries after taking Ozempic or Wegovy are encouraged to contact Parker Waichman LLP for a free, no-obligation case review.
Contact Parker Waichman LLP Today
For a free consultation, call 1-800-YOUR-LAWYER (1-800-968-7529) or visit www.yourlawyer.com.
About Parker Waichman LLP
Parker Waichman LLP is a nationally recognized law firm committed to protecting victims of defective drugs, dangerous products, accidents, and corporate negligence. The firm has extensive experience representing clients in pharmaceutical eye injury cases, including In Re Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation and Bausch & Lomb Contact Lens Solutions Products Liability Litigation. Parker Waichman has secured billions of dollars in verdicts and settlements on behalf of injured clients.
Media Contact:
Parker Waichman LLP
Phone: 1-800-YOUR-LAWYER (1-800-968-7529)
Website: www.yourlawyer.com
SOURCE Parker Waichman LLP
